Knee osteoarthritis (knee OA) is a common degenerative joint condition where cartilage wear, inflammation of the synovium, and changes in bone and soft tissues can lead to pain, stiffness, swelling, and reduced mobility often making everyday activities like stairs, walking, and standing up more difficult. Many patients try standard options such as exercise therapy, weight management, medications, injections, and physical therapy, yet still struggle with symptoms. As a result, interest in stem cell therapy for knee osteoarthritis has increased. This article explains how mesenchymal stem cell (MSC) approaches, especially umbilical cord–derived MSCs (UC-MSCs) are being studied for knee OA, what research suggests so far, and how to think about realistic expectations.
What are mesenchymal stem cells (MSCs) and why are they studied for knee OA?
Mesenchymal stem cells often called mesenchymal stromal cells (MSCs) in scientific literature are studied because they release a wide range of signaling molecules (growth factors, cytokines, and extracellular vesicles) that may help regulate inflammation and support tissue repair. In knee osteoarthritis, the problem is not only cartilage thinning; it also involves an inflamed joint environment that contributes to pain and functional limitation. Multiple systematic reviews and meta-analyses report that MSC injections are associated with improvements in pain and function in some studies, but outcomes vary by protocol, patient selection, and study design.
How stem cell therapy may work in knee osteoarthritis
Most responsible scientific discussions do not describe MSC therapy as “rebuilding a new knee.” Instead, MSC-based approaches are typically framed as supportive regenerative signaling therapies. Proposed mechanisms include:
- Reducing joint inflammation: MSCs may help shift the inflammatory balance in the joint by modulating immune signaling, which can influence pain and swelling.
- Supporting synovial health: The synovium plays a key role in joint lubrication and inflammation. Improving synovial function may help symptoms.
- Creating a more favorable cartilage environment: MSC signaling may help support cartilage maintenance and repair pathways rather than directly replacing cartilage.
- Paracrine effects: Many proposed benefits are thought to come from the molecules MSCs release, rather than long-term survival of the injected cells.
A 2024 meta-analysis evaluating MSC efficacy and safety reflects these general mechanisms while emphasizing that protocols and results vary widely.
What the clinical evidence shows (and why it can look “mixed”)
When searching online, patients often see extremely positive claims about stem cell therapy for knee OA. The scientific evidence is more nuanced. Many trials and meta-analyses report improvements in pain and functional scores (for example WOMAC or KOOS) after MSC injections, but results differ depending on:
- Cell source (bone marrow, adipose, umbilical cord)
- Dose and preparation methods
- Severity of osteoarthritis (mild/moderate vs severe)
- Comparator treatment (placebo, hyaluronic acid, PRP, or usual care)
- Follow-up duration
Some systematic reviews conclude MSC therapy can improve pain and function in certain settings, while still rating overall certainty as low to moderate due to heterogeneity and risk of bias.
Importantly, some higher-level analyses have suggested MSC injections may provide little to no meaningful improvement for chronic knee pain related to osteoarthritis when considering stricter evidence standards. This does not mean MSCs never help, but it reinforces that results are not consistent enough for guaranteed promises or one-size-fits-all marketing.
UC-MSCs for knee OA: what’s specific about umbilical cord–derived MSCs?
Umbilical cord–derived MSCs (including Wharton’s jelly–derived MSCs) are studied because they may show strong proliferative capacity and immunomodulatory signaling characteristics in laboratory settings. A 2024 review focused on intra-articular UC-MSC injections reported improvements in pain and function, while also emphasizing limitations such as small study numbers and the need for larger, high-quality trials.
For patients, the practical takeaway is that UC-MSC approaches are promising but still evolving. Most realistic goals in responsible clinical discussions relate to pain reduction, functional improvement, and quality of life support not guaranteed cartilage regrowth seen on imaging.
Safety and what reputable bodies say about routine use
Short-term safety reporting in published studies is generally reassuring, with many trials reporting mostly temporary side effects such as swelling, soreness, or post-injection discomfort. A 2024 systematic review focused on complications found no signal of major complications in the included studies, while noting moderate rates of transient symptoms.
However, patients should also be aware of how major organizations frame the evidence. The U.S. FDA has stated that regenerative medicine therapies have not been approved for orthopedic conditions such as osteoarthritis and has published consumer information warning about unapproved regenerative products.
Similarly, an orthopedic society position statement (AAHKS) has concluded that biologic therapies including stem cell–type injections cannot currently be recommended for routine treatment of advanced hip or knee osteoarthritis due to limited evidence of superiority over standard options and important cost considerations.
Who may be a good candidate for stem cell therapy in knee OA?
Patient selection is a major factor in outcomes. In many real-world clinical contexts, MSC therapy is considered more reasonable when patients:
- Have mild to moderate knee osteoarthritis rather than advanced “bone-on-bone” collapse
- Want symptom improvement and functional support while delaying more invasive procedures
- Can commit to rehabilitation, strength training, and lifestyle support
- Do not have uncontrolled infection, major contraindications, or factors that increase risk
Even among good candidates, results can range from meaningful improvement to minimal change. Stem cell therapy should be viewed as a supportive option, not a guaranteed cure.
What a responsible knee OA program should include
A well-designed osteoarthritis program is rarely “injection only.” Better outcomes are typically associated with combining interventions, including:
- Physiotherapy and strengthening: quadriceps, hip stabilizers, mobility, balance, and gradual loading
- Weight and metabolic support: reducing joint stress and systemic inflammation can meaningfully improve symptoms
- Flare planning: safe activity modification and clinician-guided follow-up
- Tracking outcomes: baseline imaging plus functional scoring (WOMAC/KOOS) to monitor progress over time
This integrated approach matches the reality that osteoarthritis is a whole-joint condition influenced by biomechanics, inflammation, and overall health.
Bottom line
Stem cell therapy using MSCs including UC-MSCs is a fast-evolving area in regenerative medicine for knee osteoarthritis. Many studies report potential improvements in pain and function, but results vary and the overall evidence base remains debated. The most responsible way to approach MSC therapy is as an adjunct supportive option within a structured knee osteoarthritis plan that includes medical assessment, rehabilitation, and realistic goal-setting. Anyone considering this approach should consult a qualified clinician to review imaging, disease severity, potential risks, and whether treatment goals are achievable.